No Data
No Data
No Data
No Data
No Data
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
cls.cnApr 8 22:34
Express News | Guojin Securities: Focus on opportunities such as in vitro diagnostic collection clean-up and proprietary Chinese medicine collection
BreakingsApr 8 08:38
Express News | Capital Securities: The high dividend rate in the Chinese medicine industry is stable and sustainable
BreakingsApr 2 10:47
Good sector+performance catalyst, explaining in detail the differences in Tongrentang Technology (01666.HK)'s dual market expectations
Under a series of favorable policies, Tong Ren Tang Technology, as a highly recognizable and even scarce enterprise in the Hong Kong stock market, will benefit.
Gelonghui FinanceMar 25 08:47
China Traditional Chinese Medicine Posts 94% Profit Growth in 2023
China Traditional Chinese Medicine Holdings Co (HKG:0570) recorded a 93.6% rise in its net profit to 1.40 billion yuan in 2023, against 720.96 million yuan a year ago, according to a Thursday filing w
MT NewswiresMar 22 13:15
China Traditional Chinese Medicine (00570.HK)'s annual net profit of 1,396 billion yuan increased 93.6% year-on-year
Gelonghui, March 21, 丨 China Traditional Chinese Medicine (00570.HK) announced that for the year ended December 31, 2023, the company's turnover was RMB 18.1 billion, up 26.7% from the same period in 2022; net profit was RMB 1,396 billion, up 93.6% from the same period in 2022. No dividend payments were recommended for the year.
Gelonghui FinanceMar 21 22:50
No Data
No Data